Intraluminal drug and formulation behavior and integration in in vitro permeability estimation:: A case study with amprenavir

被引:81
作者
Brouwers, J
Tack, J
Lammert, F
Augustijns, P
机构
[1] Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, B-3000 Louvain, Belgium
[2] Univ Hosp Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium
[3] Univ Hosp Bonn, Dept Internal Med 1, D-53105 Bonn, Germany
关键词
Caco-2; cells; intestinal absorption; amprenavir; TPGS; P-glycoprotein; biorelevance; human intestinal fluid;
D O I
10.1002/jps.20553
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to assess the effect of biorelevant apical conditions on intestinal permeability estimation in the Caco-2 system for amprenavir, a poorly water-soluble substrate of the efflux carrier P-glycoprotein (P-gp). To establish biorelevant conditions, human intestinal fluids (HIF) were aspirated from the duodenum and jejunum in fasted subjects, before and during 4 h after the intake of a standard formulation of amprenavir (Agenerase(R)). The HIF samples were characterized with respect to the concentrations of phospholipids, individual bile salts, amprenavir, and the excipient d-alpha-tocopheryl polyethyleneglycol 1000 succinate (TPGS); subsequently, the use of these samples in the Caco-2 system during permeability estimation for amprenavir was compared to standard conditions (amprenavir 10 mu M dissolved in HBSS-based transport medium). The presence of the solubilizing excipient TPGS resulted in high intraluminal amprenavir concentrations (mM-range) and affected the permeability in a concentration-dependent way. At the observed intraluminal TPGS concentrations (mM-range), TPGS appeared to completely inhibit the interaction between amprenavir and P-gp, suggesting that the effect of P-gp on transepithelial transport of amprenavir in a clinical setting is probably negligible. This study illustrates the importance of the evaluation of intraluminal conditions after drug intake and their integration in permeability estimation in vitro. (C) 2005 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:372 / 383
页数:12
相关论文
共 29 条
[1]   Transport activity of human MRP3 expressed in Sf9 cells: Comparative studies with rat MRP3 [J].
Akita, H ;
Suzuki, H ;
Hirohashi, T ;
Takikawa, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2002, 19 (01) :34-41
[2]   P-glycoprotein and surfactants: Effect on intestinal talinolol absorption [J].
Bogman, K ;
Zysset, Y ;
Degen, L ;
Hopfgartner, G ;
Gutmann, H ;
Alsenz, J ;
Drewe, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :24-32
[3]  
BOUDREAUX JP, 1993, TRANSPLANT P, V25, P1875
[4]   Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form [J].
Brouwers, J ;
Ingels, F ;
Tack, J ;
Augustijns, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (08) :987-995
[5]   The effect of water-soluble vitamin E On cyclosporine pharmacokinetics in healthy volunteers [J].
Chang, T ;
Benet, LZ ;
Hebert, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (03) :297-303
[6]   P-glycoprotein attenuating effect of human intestinal fluid [J].
Deferme, S ;
Tack, J ;
Lammert, F ;
Augustijns, P .
PHARMACEUTICAL RESEARCH, 2003, 20 (06) :900-903
[7]   Plasma alpha-tocopherol concentrations after supplementation with water- and fat-soluble vitamin E [J].
Dimitrov, NV ;
MeyerLeece, C ;
McMillan, J ;
Gilliland, D ;
Perloff, M ;
Malone, W .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (03) :329-335
[8]   Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) [J].
Dintaman, JM ;
Silverman, JA .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1550-1556
[9]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[10]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705